All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche and sobi, and supported through educational grants from Bristol Myers Squibb, Incyte and Lilly. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lymphoma & CLL content recommended for you
During the 18th International Conference on Malignant Lymphoma (ICML), June 17–21, 2025, Lugano, CH, the Lymphoma Hub held a symposium on June 17, 2025, titled Customizing therapy for mantle cell lymphoma (MCL). The symposium was chaired by Gilles Salles, with presentations from Julie Vose, Wojciech Jurczak, and Michael Wang, and concluded with a Q&A session that included live audience participation. Explore each session below:
Julie Vose, University of Nebraska Medical Center, Omaha, US, presented the first session at the recent Lymphoma Hub symposium, titled ‘Customizing therapy for mantle cell lymphoma’ hosted at the 18th International Conference on Malignant Lymphoma, June 17–21, 2025, Lugano, CH.
.webp)
Wojciech Jurczak, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, PL, presented the second session at the recent Lymphoma Hub symposium, titled ‘Customizing therapy for mantle cell lymphoma’, hosted at the 18th International Conference on Malignant Lymphoma, June 17–21, 2025, Lugano, CH.
.webp)
Michael Wang, MD Anderson Cancer Center, Houston, US, presented the third session at the recent Lymphoma Hub symposium, titled ‘Customizing therapy for mantle cell lymphoma’ hosted at the 18th International Conference on Malignant Lymphoma, June 17–21, 2025, Lugano, CH.
.webp)
The Lymphoma Hub symposium titled ‘Customizing therapy for mantle cell lymphoma’, hosted at the 18th International Conference on Malignant Lymphoma, concluded with a Q&A session, where panelists Gilles Salles, Julie Vose, Wojciech Jurczak, and Michael Wang answered questions from the live audience.
This educational resource is independently supported by Eli Lilly and Company. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
In your experience, when do most CRS/ICANS events occur after lisocabtagene maraleucel infusion?
Julie Vose
Gilles Salles
Wojciech Jurczak
Michael Wang